Hemoglobin level trajectories in the early treatment period are related with survival outcomes in patients with breast cancer

Chia Lin Lee, Chun Hao Tsai, Dah Cherng Yeh, Chi Shy Lin, Yu Fen Li, Huey En Tzeng

Research output: Contribution to journalArticle

Abstract

Hemoglobin (Hb) levels are reportedly related with treatment outcomes and survival in patients of breast cancer. However, the long-term change in Hb levels after treatment and the effects of Hb on survival remain unknown. This retrospective cohort study enrolled 1931 breast cancer patients with pathological stage I-IV between 1/1/2003 and 12/31/2013. Latent class modeling was used to identify trajectories in monthly Hb levels over time. The primary endpoint was 10-year cancer-related death. We identified 5 distinct Hb trajectories: persistent anemia (5.6 %; n = 109), improved anemia (4.8 %, n = 93), mild anemia (21.0%; n = 406), low normal Hb (46.6 %; n = 899), and normal Hb (21.9%; n = 424). Compared with the normal-Hb group, trajectories with low Hb levels had worst 10-year survival. The adjusted hazard ratios were 1.79(95% CI, 0.91-3.53) for the improved anemia group, 1.09(95% CI, 0.68-1.74) for the mild anemia group, 1.06 (95% CI, 0.71-1.60) for the low normal Hb group, and 2.19(95% CI 1.28-3.75) for the persistent anemia group. Our findings show there are five Hb level trajectories during breast cancer treatment. The anemia Hb level trajectory during the first 12 months after treatment reflect the worst cancerrelated 10-year survival in breast cancer patients.

Original languageEnglish
Pages (from-to)1569-1579
Number of pages11
JournalOncotarget
Volume8
Issue number1
DOIs
Publication statusPublished - Jan 1 2017
Externally publishedYes

Fingerprint

Hemoglobins
Breast Neoplasms
Survival
Anemia
Therapeutics
Cohort Studies
Retrospective Studies

Keywords

  • Breast cancer
  • Hemoglobin
  • Survival
  • Trajectory

ASJC Scopus subject areas

  • Oncology

Cite this

Hemoglobin level trajectories in the early treatment period are related with survival outcomes in patients with breast cancer. / Lee, Chia Lin; Tsai, Chun Hao; Yeh, Dah Cherng; Lin, Chi Shy; Li, Yu Fen; Tzeng, Huey En.

In: Oncotarget, Vol. 8, No. 1, 01.01.2017, p. 1569-1579.

Research output: Contribution to journalArticle

Lee, Chia Lin ; Tsai, Chun Hao ; Yeh, Dah Cherng ; Lin, Chi Shy ; Li, Yu Fen ; Tzeng, Huey En. / Hemoglobin level trajectories in the early treatment period are related with survival outcomes in patients with breast cancer. In: Oncotarget. 2017 ; Vol. 8, No. 1. pp. 1569-1579.
@article{a746519043cc4150a7130b9ce8347fd3,
title = "Hemoglobin level trajectories in the early treatment period are related with survival outcomes in patients with breast cancer",
abstract = "Hemoglobin (Hb) levels are reportedly related with treatment outcomes and survival in patients of breast cancer. However, the long-term change in Hb levels after treatment and the effects of Hb on survival remain unknown. This retrospective cohort study enrolled 1931 breast cancer patients with pathological stage I-IV between 1/1/2003 and 12/31/2013. Latent class modeling was used to identify trajectories in monthly Hb levels over time. The primary endpoint was 10-year cancer-related death. We identified 5 distinct Hb trajectories: persistent anemia (5.6 {\%}; n = 109), improved anemia (4.8 {\%}, n = 93), mild anemia (21.0{\%}; n = 406), low normal Hb (46.6 {\%}; n = 899), and normal Hb (21.9{\%}; n = 424). Compared with the normal-Hb group, trajectories with low Hb levels had worst 10-year survival. The adjusted hazard ratios were 1.79(95{\%} CI, 0.91-3.53) for the improved anemia group, 1.09(95{\%} CI, 0.68-1.74) for the mild anemia group, 1.06 (95{\%} CI, 0.71-1.60) for the low normal Hb group, and 2.19(95{\%} CI 1.28-3.75) for the persistent anemia group. Our findings show there are five Hb level trajectories during breast cancer treatment. The anemia Hb level trajectory during the first 12 months after treatment reflect the worst cancerrelated 10-year survival in breast cancer patients.",
keywords = "Breast cancer, Hemoglobin, Survival, Trajectory",
author = "Lee, {Chia Lin} and Tsai, {Chun Hao} and Yeh, {Dah Cherng} and Lin, {Chi Shy} and Li, {Yu Fen} and Tzeng, {Huey En}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.13679",
language = "English",
volume = "8",
pages = "1569--1579",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "1",

}

TY - JOUR

T1 - Hemoglobin level trajectories in the early treatment period are related with survival outcomes in patients with breast cancer

AU - Lee, Chia Lin

AU - Tsai, Chun Hao

AU - Yeh, Dah Cherng

AU - Lin, Chi Shy

AU - Li, Yu Fen

AU - Tzeng, Huey En

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Hemoglobin (Hb) levels are reportedly related with treatment outcomes and survival in patients of breast cancer. However, the long-term change in Hb levels after treatment and the effects of Hb on survival remain unknown. This retrospective cohort study enrolled 1931 breast cancer patients with pathological stage I-IV between 1/1/2003 and 12/31/2013. Latent class modeling was used to identify trajectories in monthly Hb levels over time. The primary endpoint was 10-year cancer-related death. We identified 5 distinct Hb trajectories: persistent anemia (5.6 %; n = 109), improved anemia (4.8 %, n = 93), mild anemia (21.0%; n = 406), low normal Hb (46.6 %; n = 899), and normal Hb (21.9%; n = 424). Compared with the normal-Hb group, trajectories with low Hb levels had worst 10-year survival. The adjusted hazard ratios were 1.79(95% CI, 0.91-3.53) for the improved anemia group, 1.09(95% CI, 0.68-1.74) for the mild anemia group, 1.06 (95% CI, 0.71-1.60) for the low normal Hb group, and 2.19(95% CI 1.28-3.75) for the persistent anemia group. Our findings show there are five Hb level trajectories during breast cancer treatment. The anemia Hb level trajectory during the first 12 months after treatment reflect the worst cancerrelated 10-year survival in breast cancer patients.

AB - Hemoglobin (Hb) levels are reportedly related with treatment outcomes and survival in patients of breast cancer. However, the long-term change in Hb levels after treatment and the effects of Hb on survival remain unknown. This retrospective cohort study enrolled 1931 breast cancer patients with pathological stage I-IV between 1/1/2003 and 12/31/2013. Latent class modeling was used to identify trajectories in monthly Hb levels over time. The primary endpoint was 10-year cancer-related death. We identified 5 distinct Hb trajectories: persistent anemia (5.6 %; n = 109), improved anemia (4.8 %, n = 93), mild anemia (21.0%; n = 406), low normal Hb (46.6 %; n = 899), and normal Hb (21.9%; n = 424). Compared with the normal-Hb group, trajectories with low Hb levels had worst 10-year survival. The adjusted hazard ratios were 1.79(95% CI, 0.91-3.53) for the improved anemia group, 1.09(95% CI, 0.68-1.74) for the mild anemia group, 1.06 (95% CI, 0.71-1.60) for the low normal Hb group, and 2.19(95% CI 1.28-3.75) for the persistent anemia group. Our findings show there are five Hb level trajectories during breast cancer treatment. The anemia Hb level trajectory during the first 12 months after treatment reflect the worst cancerrelated 10-year survival in breast cancer patients.

KW - Breast cancer

KW - Hemoglobin

KW - Survival

KW - Trajectory

UR - http://www.scopus.com/inward/record.url?scp=85009823663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009823663&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.13679

DO - 10.18632/oncotarget.13679

M3 - Article

AN - SCOPUS:85009823663

VL - 8

SP - 1569

EP - 1579

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 1

ER -